Key result
Prolonged pretreatment of HeLa cells with CVB3-specific phosphorothioate oligodeoxynucleotides inhibited viral replication, though efficacy was likely limited by low cellular uptake.
Why the study?
Do CVB3-specific phosphorothioate oligodeoxynucleotides inhibit CVB3 replication in HeLa cells?
Population
HeLa cells infected with Coxsackievirus B3 (CVB3)
Comparison
Coxsackievirus B3-specific phosphorothioate… vs Simultaneous application of virus and PS-ODN
Design
Preclinical
Authors
Loading...
Uptake barriers limit near-term antiviral utility; leaves open optimized PS-ODNs for CVB3 after delivery improvements.
Do CVB3-specific phosphorothioate oligodeoxynucleotides inhibit CVB3 replication in HeLa cells?
CVB3-specific PS-ODNs require prolonged pretreatment to inhibit viral replication in vitro, likely due to low cellular uptake.
Schmidtke et al. (1998) studied Coxsackievirus B3 (CVB3) infection. Coxsackievirus B3 (CVB3)-specific phosphorothioate oligodeoxynucleotides (PS-ODNs) vs. Simultaneous application of virus and PS-ODN was evaluated on Inhibition of CVB3 replication. Prolonged pretreatment of HeLa cells with CVB3-specific phosphorothioate oligodeoxynucleotides inhibited viral replication, though efficacy was likely limited by low cellular uptake.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: